Payment overview · 2025
General Payments
$618.28
31 reported records · 12 companies
Healthcare provider profile · identity verified
Michael Soler, MD
Allopathic & Osteopathic Physicians|Family Medicine · PORTLAND, TX · NPI 1285901140
Verified facts
What the public records show
CMS Open Payments records show Michael Soler, MD received $618.28 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.35 | 23.0% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.85 | 15.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.61 | 11.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.34 | 9.8% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $54.31 | 8.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.00 | 8.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.84 | 6.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.77 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.55 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.67 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.67 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.32 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $618.28 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.35 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $95.85 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.34 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $54.31 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.62 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 210 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
210 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 716 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 607 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 123 |
| Lisinopril | Lisinopril | 430 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 122 |
| Prednisone | Prednisone | 302 | 201 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 91 |
| Metformin Hcl | Metformin Hcl | 291 | 92 |
| Alprazolam | Alprazolam | 240 | 61 |
| Losartan Potassium | Losartan Potassium | 229 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 86 |
| Gabapentin | Gabapentin | 222 | 76 |
| Mounjaro | Tirzepatide | 210 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 53 |
| Meloxicam | Meloxicam | 199 | 69 |
| Azithromycin | Azithromycin | 192 | 149 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 57 |
| Furosemide | Furosemide | 189 | 71 |
| Trazodone Hcl | Trazodone Hcl | 187 | 55 |
| Famotidine | Famotidine | 185 | 58 |
| Montelukast Sodium | Montelukast Sodium | 167 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 49 |
| Simvastatin | Simvastatin | 159 | 50 |
| Baclofen | Baclofen | 143 | 68 |
| Clonazepam | Clonazepam | 142 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 139 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 37 |
| Valsartan | Valsartan | 125 | 39 |
| Omeprazole | Omeprazole | 119 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 35 |
| Potassium Chloride | Potassium Chloride | 117 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 31 |
| Tramadol Hcl | Tramadol Hcl | 102 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 101 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 34 |
| Jardiance | Empagliflozin | 86 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 28 |
| Sertraline Hcl | Sertraline Hcl | 85 | 19 |
| Mupirocin | Mupirocin | 83 | 62 |
| Allopurinol | Allopurinol | 76 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 13 |
| Carvedilol | Carvedilol | 75 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 75 | 59 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Glipizide | Glipizide | 74 | 22 |
| Celecoxib | Celecoxib | 70 | 24 |
| Ozempic | Semaglutide | 69 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 16 |
| Eliquis | Apixaban | 64 | 16 |
| Pregabalin | Pregabalin | 62 | 20 |
| Finasteride | Finasteride | 61 | 17 |
| Donepezil Hcl | Donepezil Hcl | 59 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Cefdinir | Cefdinir | 55 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 18 |
| Meclizine Hcl | Meclizine Hcl | 55 | 16 |
| Ondansetron Odt | Ondansetron | 53 | 18 |
| Bupropion Xl | Bupropion Hcl | 52 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 16 |
| Diazepam | Diazepam | 51 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 48 | 14 |
| Spironolactone | Spironolactone | 47 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 16 |
| Methocarbamol | Methocarbamol | 45 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Temazepam | Temazepam | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 36 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Fentanyl | Fentanyl | 33 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Constulose | Lactulose | 31 | 21 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 28 |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | 11 |
| Cephalexin | Cephalexin | 28 | 25 |
| Estradiol | Estradiol | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | 12 |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 20 |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Nystatin | Nystatin | 25 | 18 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Lactulose | Lactulose | 23 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Risperidone | Risperidone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 11 |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $618.28 · 31 records | Novo Nordisk Inc | BREZTRI, CREON, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error